Journal article · 2024 · Open access
One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial
Vaccine, 42(6), 1319–1325 · Published 1 February 2024 · DOI 10.1016/j.vaccine.2024.01.056
In brief
“One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial” is a 2024 journal article by Kenji Kuriyama and 6 co-authors, published in Vaccine. OpenAlex counts 6 citations as of 20 November 2026. It is open access under a CC BY licence: the full text is free to read at Vaccine.
- Citations
- 6
- Most cited in
- 2025 (4)
- Field-weighted impact
- 1.52
- References
- 10
- Authors
- 7
Abstract
BACKGROUND: In the interim report of this phase I/II randomized, placebo-controlled trial in Japanese adults, a two-dose primary series of NVX-CoV2373 (5 µg SARS-CoV-2 recombinant nanoparticle spike protein [rS]; 50 µg Matrix-M) administered 21 days apart induced robust anti-SARS-CoV-2 immune responses up to day 50 and had an acceptable safety profile. METHODS: Following the double-blind phase of this study (day 1-50), participants were informed about their assignment to NVX-CoV2373 or placebo, and their reconsent was required for continuation in the open-label phase (day 51-387). This final report evaluated immunogenicity on days 202 and 387, and safety findings from the 1-year follow-up. RESULTS: In total, 131/150 participants in the NVX-CoV2373 arm and 4/50 in the placebo arm completed the study. The most common reason for discontinuation was because the participant requested a publicly available COVID-19 vaccine. At 6 months and 1 year after the second vaccine dose, both the geometric mean titres of anti-SARS-CoV-2 rS serum immunoglobulin G and serum neutralizing antibodies against the SARS-CoV-2 ancestral strain were numerically higher than before the second dose. There were no deaths, adverse events (AEs) leading to participant withdrawal, or AEs of special interest throughout the trial. During follow-up, 2.0 % (1/50) of participants in the placebo arm reported COVID-19 approximately 1 month after the second vaccine dose (serious AE requiring hospitalisation, already presented in the interim report) and 2.7 % (4/150) in the NVX-CoV2373 arm after approximately 10 months (mild [2/4] or moderate [2/4] in severity). DISCUSSION: A primary series of NVX-CoV2373 induced persistent immune responses up to 1 year after the second dose. The vaccine was well tolerated and had an acceptable safety profile. We believe our findings offer important insights for determining dosing intervals between primary and booster vaccinations.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Kuriyama, K., Murakami, K., Sugiura, K., Sakui, S., Schuring, R. P., Masuda, T., & Mori, M. (2024). One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial. Vaccine, 42(6), 1319–1325. https://doi.org/10.1016/j.vaccine.2024.01.056
MLA 9
Kuriyama, Kenji, et al. “One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial.” Vaccine, vol. 42, no. 6, 2024, pp. 1319–1325. https://doi.org/10.1016/j.vaccine.2024.01.056.
Chicago
Kuriyama, Kenji, Kyoko Murakami, Kenkichi Sugiura, Sho Sakui, Ron P. Schuring, Taisei Masuda, and Mitsuhiro Mori. 2024. “One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial.” Vaccine 42 (6): 1319–1325. https://doi.org/10.1016/j.vaccine.2024.01.056.
Harvard
Kuriyama, K. et al. (2024) ‘One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial’, Vaccine, 42(6), pp. 1319–1325. doi:10.1016/j.vaccine.2024.01.056.
IEEE
K. Kuriyama et al., “One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial,” Vaccine, vol. 42, no. 6, pp. 1319–1325, 2024, doi: 10.1016/j.vaccine.2024.01.056.
BibTeX
@article{kuriyama2024year,
title = {{One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial}},
author = {Kuriyama, Kenji and Murakami, Kyoko and Sugiura, Kenkichi and Sakui, Sho and Schuring, Ron P. and Masuda, Taisei and Mori, Mitsuhiro},
journal = {Vaccine},
year = {2024},
volume = {42},
number = {6},
pages = {1319--1325},
doi = {10.1016/j.vaccine.2024.01.056},
url = {https://doi.org/10.1016/j.vaccine.2024.01.056}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 1 | |
| 2025 | 4 | |
| 2026 | 1 |
Its field-weighted citation impact is 1.52: it has been cited 1.52 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- NVX-CoV2373
- COVID-19 vaccines
- Matrix-M adjuvant
- long-term immunogenicity
- neutralizing antibodies
- vaccine safety
- adverse events
- Japanese adults
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Kuriyama, K., Murakami, K., Sugiura, K., Sakui, S., Schuring, R. P., Masuda, T., & Mori, M. (2024). One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial. Vaccine, 42(6), 1319–1325. https://doi.org/10.1016/j.vaccine.2024.01.056
How many times has this paper been cited?
6 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Vaccine: sign in and open the full text from this page.
Who wrote this paper?
Kenji Kuriyama, Kyoko Murakami, Kenkichi Sugiura, Sho Sakui, Ron P. Schuring, Taisei Masuda, Mitsuhiro Mori.
What is the DOI of this paper?
10.1016/j.vaccine.2024.01.056, permanently at https://doi.org/10.1016/j.vaccine.2024.01.056. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.